Campbell & Co Investment Adviser’s Beam Therapeutics BEAM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$412K	Sell	12,002 -8,371	-41%	-$253K	0.02%	827
2026 Q1	$485K	Buy	+20,373	New	+$565K	0.03%	764
2025 Q4	–	Sell	-16,614	Closed	-$403K	–	1139
2025 Q3	$403K	Sell	16,614 -210,130	-93%	-$4.18M	0.03%	809
2025 Q2	$3.86M	Buy	+226,744	New	+$3.95M	0.24%	78

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Campbell & Co Investment Adviser's BEAM Position: Q2 2026 in Review

Campbell & Co Investment Adviser reduced its Beam Therapeutics (BEAM) stake by 41% in Q2 2026, selling an estimated $253K and leaving 12,002 shares worth $412K. The position accounts for 0.02% of the portfolio, ranked #827.

Campbell & Co Investment Adviser first reported a position in BEAM in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.86M in Q2 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Campbell & Co Investment Adviser held 12,002 shares of Beam Therapeutics worth $412K as of Q2 2026.
Campbell & Co Investment Adviser sold 8,371 Beam Therapeutics shares in Q2 2026, an estimated $253K.
Beam Therapeutics made up 0.02% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #827 holding.
Campbell & Co Investment Adviser first reported a position in Beam Therapeutics in Q2 2025 and has held it in 4 quarters since.
Campbell & Co Investment Adviser's Beam Therapeutics position peaked at $3.86M in Q2 2025.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.